Acumen Pharmaceuticals Stock Performance
| ABOS Stock | USD 2.59 0.01 0.38% |
On a scale of 0 to 100, Acumen Pharmaceuticals holds a performance score of 7. The firm shows a Beta (market volatility) of 0.95, which signifies possible diversification benefits within a given portfolio. Acumen Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Acumen Pharmaceuticals is expected to follow. Please check Acumen Pharmaceuticals' value at risk, as well as the relationship between the skewness and price action indicator , to make a quick decision on whether Acumen Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Acumen Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Acumen Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.38) | Five Day Return (9.44) | Year To Date Return 28.22 | Ten Year Return (87.11) | All Time Return (87.11) |
1 | Acumen Pharmaceuticals, Inc. Q3 2025 Earnings Call Transcript | 11/13/2025 |
2 | Retail Surge Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline - 2025 Pullback Review Fast Entry Momentum Alerts - | 12/18/2025 |
3 | Disposition of 4000 shares by Barton Russell of Acumen Pharmaceuticals at 1.9581 subject to Rule 16b-3 | 01/05/2026 |
4 | Disposition of 3618 shares by Barton Russell of Acumen Pharmaceuticals at 1.9664 subject to Rule 16b-3 | 01/06/2026 |
5 | Disposition of 1700 shares by Barton Russell of Acumen Pharmaceuticals at 1.9871 subject to Rule 16b-3 | 01/07/2026 |
6 | Disposition of 12941 shares by Oconnell Daniel Joseph of Acumen Pharmaceuticals at 1.7643 subject to Rule 16b-3 | 01/09/2026 |
7 | Daniel Joseph Oconnell Sells 8,143 Shares of Acumen Pharmaceuticals Stock | 01/13/2026 |
8 | Acquisition by James Doherty of 166867 shares of Acumen Pharmaceuticals subject to Rule 16b-3 | 01/16/2026 |
9 | Acquisition by Oconnell Daniel Joseph of 450000 shares of Acumen Pharmaceuticals at 1.86 subject to Rule 16b-3 | 01/20/2026 |
10 | Disposition of 2315 shares by Barton Russell of Acumen Pharmaceuticals at 1.806 subject to Rule 16b-3 | 01/21/2026 |
11 | Disposition of 462 shares by Barton Russell of Acumen Pharmaceuticals at 1.84 subject to Rule 16b-3 | 01/22/2026 |
12 | Disposition of 5633 shares by Meisner Derek M of Acumen Pharmaceuticals at 1.9027 subject to Rule 16b-3 | 01/23/2026 |
13 | Disposition of 2671 shares by Meisner Derek M of Acumen Pharmaceuticals at 1.85 subject to Rule 16b-3 | 01/28/2026 |
| Begin Period Cash Flow | 67.1 M | |
| Total Cashflows From Investing Activities | 48 M |
Acumen Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 203.00 in Acumen Pharmaceuticals on November 5, 2025 and sell it today you would earn a total of 56.00 from holding Acumen Pharmaceuticals or generate 27.59% return on investment over 90 days. Acumen Pharmaceuticals is currently generating 0.5846% in daily expected returns and assumes 6.244% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Acumen, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acumen Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Acumen Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.59 | 90 days | 2.59 | about 1.44 |
Based on a normal probability distribution, the odds of Acumen Pharmaceuticals to move above the current price in 90 days from now is about 1.44 (This Acumen Pharmaceuticals probability density function shows the probability of Acumen Stock to fall within a particular range of prices over 90 days) .
Acumen Pharmaceuticals Price Density |
| Price |
Predictive Modules for Acumen Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Acumen Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Acumen Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Acumen Pharmaceuticals is not an exception. The market had few large corrections towards the Acumen Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Acumen Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Acumen Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.31 | |
β | Beta against Dow Jones | 0.95 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | 0.05 |
Acumen Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Acumen Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Acumen Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Acumen Pharmaceuticals is way too risky over 90 days horizon | |
| Acumen Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Acumen Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (102.33 M) with loss before overhead, payroll, taxes, and interest of (118.93 M). | |
| Acumen Pharmaceuticals currently holds about 189.91 M in cash with (86.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Disposition of 2671 shares by Meisner Derek M of Acumen Pharmaceuticals at 1.85 subject to Rule 16b-3 |
Acumen Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Acumen Stock often depends not only on the future outlook of the current and potential Acumen Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acumen Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 60 M | |
| Cash And Short Term Investments | 171.6 M |
Acumen Pharmaceuticals Fundamentals Growth
Acumen Stock prices reflect investors' perceptions of the future prospects and financial health of Acumen Pharmaceuticals, and Acumen Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acumen Stock performance.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 73.23 M | ||||
| Shares Outstanding | 60.57 M | ||||
| Price To Book | 1.69 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (118.93 M) | ||||
| EBITDA | (98.08 M) | ||||
| Net Income | (102.33 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 29.7 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | (86.22 M) | ||||
| Earnings Per Share | (2.21) X | ||||
| Market Capitalization | 157.49 M | ||||
| Total Asset | 238.99 M | ||||
| Retained Earnings | (325.13 M) | ||||
| Working Capital | 150.7 M | ||||
About Acumen Pharmaceuticals Performance
Assessing Acumen Pharmaceuticals' fundamental ratios provides investors with valuable insights into Acumen Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acumen Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.40) | |
| Return On Capital Employed | (0.49) | (0.51) | |
| Return On Assets | (0.39) | (0.40) | |
| Return On Equity | (0.65) | (0.61) |
Things to note about Acumen Pharmaceuticals performance evaluation
Checking the ongoing alerts about Acumen Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acumen Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acumen Pharmaceuticals is way too risky over 90 days horizon | |
| Acumen Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Acumen Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (102.33 M) with loss before overhead, payroll, taxes, and interest of (118.93 M). | |
| Acumen Pharmaceuticals currently holds about 189.91 M in cash with (86.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Disposition of 2671 shares by Meisner Derek M of Acumen Pharmaceuticals at 1.85 subject to Rule 16b-3 |
- Analyzing Acumen Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acumen Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Acumen Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acumen Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acumen Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acumen Pharmaceuticals' stock. These opinions can provide insight into Acumen Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.